Reach Us +44-1904-929220
Development Of High Sensitivity Bioluminescent Enzyme Immunoassay For Oxytocin As Biomarkers For Psychiatric Disorder | 3699

Journal of Molecular Biomarkers & Diagnosis
Open Access

Like us on:

OMICS International organises 3000+ Global Conferenceseries Events every year across USA, Europe & Asia with support from 1000 more scientific Societies and Publishes 700+ Open Access Journals which contains over 50000 eminent personalities, reputed scientists as editorial board members.

Open Access Journals gaining more Readers and Citations
700 Journals and 15,000,000 Readers Each Journal is getting 25,000+ Readers

This Readership is 10 times more when compared to other Subscription Journals (Source: Google Analytics)

Development of high sensitivity bioluminescent enzyme immunoassay for oxytocin as biomarkers for psychiatric disorder

2nd World Congress on Biomarkers & Clinical Research

Yoshihiro Sano, Shiomi Ohta, Hiroshi Ohkuma, Haruhumi Tsuge and Hidetoshi Arakawa

Posters: J Mol Biomark Diagn

DOI: 10.4172/2155-9929.S1.3

Autistic spectrum disorder (ASD) is known as a disease of wide prevalence in children. DSM-IV is currently used as the diagnosis of ASD in clinical psychiatry. However, it is diffi cult to provide a defi nitive diagnosis of ASD. As the reason, characteristics of ASD are very similar to that of schizophrenia or social anxiety disorder. Th erefore, if children develop ASD until in early childhood and cannot be received treatment, they will have a high risk secondary disorder, depression etc. As a result, development of simple clinical laboratory test for ASD is necessary for early detection and rapid cure of that disorder. Recently, it has been suggested that ASD patients have low level of OXT in their plasma. Th erefore, OXT might be able to be used as one of the biomarker for ASD, psychiatric disorder. In this report, we developed highly sensitive bioluminescent enzyme immunoassay (BLEIA) for OXT utilizing the Luciferin/luciferase detection system. On this assay, the detection limit was 1 pg/assay (B0-3SD). Additionally, in the result of the cross reactivity examination, we conclude that BLEIA was developed high sensitively and specifi cally measurement for OXT. But it might not be able to measure of OXT in plasma of ASD patients, which is estimated to very low level. Finally, we will propose to the modifi cation of secondary antibody immobilized magnetic particles preparation, assay protocol and labeled antigen or re-selection of anti-OXT antibody, to contribute as clinical laboratory test for psychiatric disorder, ASD
Yoshihiro Sano has completed his Ph.D at the age of 28 years from Showa University. His work is development of high sensitive analytical method for peptide hormone etc, now.
Relevant Topics